CUAJ, E. (2026). Enfortumab Vedotin (EV) and Pembrolizumab (Pembro) Combination Treatment for Patients with Urological Cancers – Adverse Events (AEs): Management Tool Kit. Canadian Urological Association Journal, 15(1X). Retrieved from https://cuaj.ca/index.php/journal/article/view/9883